Gujarat Themis Biosyn to buy Japan's MicroBiopharm for INR 1,300 crores

The signal: MicroBiopharm JapanDealroom has a profile for this one. Try Dealroom → operates as a contract development and manufacturing organisation for the biotechnology and pharmaceutical sectors — a segment in high demand as drugmakers increasingly outsource complex biologics production. For Gujarat Themis, a mature-stage company, acquiring a breakout-stage CDMO gives it ready-made manufacturing capabilities and direct access to one of the world's largest pharmaceutical markets without building from scratch.

Read more: equitybulls.com